Cantor Fitzgerald upgraded shares of Bradmer Pharmaceuticals (TSE:GLX – Free Report) to a strong-buy rating in a research report sent to investors on Wednesday morning,Zacks.com reports.
Separately, HC Wainwright raised Bradmer Pharmaceuticals to a “strong-buy” rating in a report on Thursday, October 10th.
Check Out Our Latest Research Report on Bradmer Pharmaceuticals
Bradmer Pharmaceuticals Price Performance
Recommended Stories
- Five stocks we like better than Bradmer Pharmaceuticals
- The 3 Best Fintech Stocks to Buy Now
- Nebius Group: Market Overreaction or Real AI Disruption?
- How to Invest in Blue Chip Stocks
- The Best Way to Invest in Gold Is…
- The How and Why of Investing in Gold Stocks
- Why Nike Stock Could Be 2025’s Top Comeback Play
Receive News & Ratings for Bradmer Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bradmer Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
-logo.png?v=20240604134456&h=45&w=95&zc=2){kind=logo}
